Argenica Therapeutics Ltd

AU:AGN Australia Biotechnology

Market Cap

$15.91 Million

AU$25.69 Million AUD

Market Cap Rank

#27940 Global

#702 in Australia

Share Price

AU$0.20

Change (1 day)

+0.00%

52-Week Range

AU$0.20 - AU$0.86

All Time High

AU$0.99

Argenica Therapeutics Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.52%

Argenica Therapeutics Ltd (AGN) has an Asset Resilience Ratio of 0.52% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$50.00K

Cash + Short-term Investments

Total Assets

AU$9.54 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Argenica Therapeutics Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Argenica Therapeutics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$50.00K	0.52%
Total Liquid Assets	AU$50.00K	0.52%

Asset Resilience Insights

Limited Liquidity: Argenica Therapeutics Ltd maintains only 0.52% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.